Send us a text

Thijs Spoor is Chief Executive Officer at Perspective Therapeutics ( https://perspectivetherapeutics.com/ ), a clinical-stage, radiopharmaceutical company that is pioneering innovative treatments for cancers. The Company’s proprietary technology utilizes the alpha emitting isotope Pb-212 to deliver powerful radiation directly to cancer cells via high-affinity targeting peptides.
Prior to this, Thijs was the Chairman at Verifi H2O. Thijs also held the position of Chief Executive Officer at Viewpoint Molecular Targeting, Inc. and KBP BioSciences.
Thijs also has served as CEO at AzurRx BioPharma, where they focused on developing targeted therapies for gastrointestinal diseases, and CEO at FluoroPharma, a company focused on the discovery, development, and commercialization novel molecular positron emission tomography (PET) agents for the cardiovascular, oncology and neurology arenas.
Thijs also worked as a Strategy Consultant at Oliver Wyman, a Biotechnology Analyst at J.P. Morgan, and a Medical Devices Analyst at Credit Suisse.
Thijs began their career at GE Healthcare, where he served as the Director of Strategic Marketing and played a key role in reshaping the company's strategic directions in various areas.
Thijs completed his Bachelor of Science in Pharmacy from the University of Toronto and an MBA in Finance from Columbia Business School.
#ThijsSpoor #PerspectiveTherapeutics #Radiopharmaceuticals #NuclearMedicine #Cancer #Oncology #AlphaEmittingIsotopes #AlphaParticles #BetaParticles #Radiation #Lead #Pb212 #Lutetium #Actinium #CellTargetingPeptide #Chelator #Linker #NeuroendocrineTumors #SomatostatinReceptorSubtype2 #Melanoma #Theranostic #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show